Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Rallybio Corporation (RLYB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17,09, with a market capitalisation of $87,68M and a P/E ratio of 2,01. Over the past 52 weeks, its price has ranged from $3,67 to $17,57. This page covers its latest market performance, valuation, price trends and company information.
$87,68M | |
$16,49 | |
$206,24 | |
$1,76 | |
$16,51 | |
20,53K | |
29,27K | |
2,01 | |
$17,57 | |
$3,67 | |
-- | |
-- |
Rallybio Corporation (RLYB) is trading at $16,78 in pre-market trading as of 2026-09-15 23:31:00, up 1,61% ($0,26) from the previous close of $16,51
Pre-market trading shows how investors are pricing RLYB before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Rallybio Corporation (RLYB) moved from $16,93 to $17,09, representing a gain of 0,95% ($0,16).
The stock traded between $16,45 and $17,22 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 9,92 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 96,5%
RLYB is currently trading at $17,09, placing it 96,5% of the way from its 52-week low of $3,67 to its 52-week high of $17,57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rallybio Corporation (RLYB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.